Latest news with #IainWilkie
News.com.au
7 days ago
- Business
- News.com.au
ASX health May winners: Sector rises 1.59pc but market volatility remains
The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump's trade and health policies continue to impact sector Lumos up 7.4% in May after several positive announcements including largest single purchase order for point-of-care respiratory test The S&P/ASX 200 Health Care Index rose 1.59% in May, easing from a 2.16% gain in April but still finishing in the green. However, the sector is still not faring well and is the worst-performing year-to-date, down 5.65%. The sector rose in line with broader markets in May with the S&P/ASX 200 gaining 4.20% as fears around escalating US tariffs and a potential US-China trade war eased, bringing relief to global markets. Morgans healthcare analyst Iain Wilkie told Stockhead that 2025 had been very volatile for the sector. "Each month seems to be either up or down and the sector hasn't gained any real momentum at this stage," he said. Wilkie said US President Donald Trump and his trade and health policies were still impacting the sector. "It's just uncertainty which is driving everything at the moment," he said. In May Trump signed an executive order lowering prices of US prescription medicines to bring them in line with other countries, a policy referred to as the 'most favored nation' (MFN). The MFN policy aims to link US drug prices to much lower prices overseas – what Trump referred to as 'equalizing' prices. Trump said the order aimed to cut US pharmaceutical prices from between 59% to 90% and sets price targets for drugmakers to meet within 30 days and warns that further action will be taken if they fail to make 'significant progress' toward those goals. In a release The White House said the US had less than 5% of the world's population and yet funds around three quarters of global pharmaceutical profits. "There's no clear path on what happens next and consequences pharmaceutical companies may face," Wilkie said. "But its just created further uncertainty in the healthcare and pharmaceutical sectors in an already uncertain time." How ASX biotechs performed in May CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP DVL Dorsavi Ltd $ 0.02 36.4% 10.97 IVX Invion Ltd $ 0.11 28.0% 8.47 CC5 Clever Culture $ 0.02 26.7% 33.55 VFX Visionflex Group Ltd $ 0.003 25.0% 8.42 NYR Nyrada Inc $ 0.18 24.1% 37.97 IIQ Inoviq Ltd $ 0.55 23.9% 63.07 OSX Osteopore Limited $ 0.02 21.4% 2.95 PEB Pacific Edge $ 0.09 18.7% 60.89 ICR Intelicare Holdings $ 0.01 14.3% 3.89 MVP Medical Developments $ 0.67 11.7% 75.48 PCK Painchek Ltd $ 0.06 11.5% 106.83 IRX Inhalerx Limited $ 0.03 11.1% 6.40 ALA Arovella Therapeutic $ 0.08 11.0% 88.79 IPD Impedimed Limited $ 0.03 10.0% 66.91 LGP Little Green Pharma $ 0.11 10.0% 34.96 ATH Alterity Therapeutics $ 0.01 10.0% 100.40 DOC Doctor Care Anywhere $ 0.11 10.0% 38.50 AGH Althea Group $ 0.03 8.7% 20.56 ALC Alcidion Group Ltd $ 0.09 8.6% 114.15 HMD Heramed Limited $ 0.01 8.3% 11.38 MDR Medadvisor Limited $ 0.09 8.1% 57.48 RAD Radiopharm $ 0.03 8.0% 65.35 LDX Lumos Diagnostics $ 0.03 7.4% 21.71 AVR Anteris Technologies $ 6.29 6.6% 99.41 AFP AFT Pharmaceuticals $ 2.60 6.1% 272.65 ARX Aroa Biosurgery $ 0.49 5.4% 165.55 UCM Uscom Limited $ 0.02 5.3% 4.76 RHC Ramsay Health Care $ 37.90 5.1% 7,049.83 CVB Curvebeam Ai Limited $ 0.09 4.9% 26.97 REG Regis Healthcare Ltd $ 8.13 4.9% 1,242.92 TRI Trivarx Ltd $ 0.01 4.8% 6.79 ACR Acrux Limited $ 0.02 4.3% 9.79 VLS Vita Life Sciences $ 1.89 4.1% 104.29 PGC Paragon Care Limited $ 0.40 3.9% 662.12 NSB Neuroscientific $ 0.06 3.8% 7.95 CMP Compumedics Limited $ 0.28 3.7% 53.82 SPL Starpharma Holdings $ 0.09 3.4% 38.48 NOX Noxopharm Limited $ 0.07 2.9% 21.04 GLH Global Health Ltd $ 0.08 2.6% 4.63 CMB Cambium Bio Limited $ 0.21 2.5% 3.75 PIQ Proteomics Int Lab $ 0.42 2.4% 59.56 SDI SDI Limited $ 0.85 2.4% 99.25 CSX Cleanspace Holdings $ 0.45 2.3% 34.81 ATX Amplia Therapeutics $ 0.05 2.0% 19.40 MVF Monash IVF Group Ltd $ 0.78 2.0% 301.97 IDX Integral Diagnostics $ 2.43 1.9% 870.95 EZZ EZZ Life Science $ 1.54 1.7% 72.65 IMC Immuron Limited $ 0.07 1.5% 15.67 FRE Firebrickpharma $ 0.07 1.5% 15.05 SHL Sonic Healthcare $ 26.62 1.4% 12,821.98 FPH Fisher & Paykel Healthcare $ 34.59 1.4% 6,585.46 IMR Imricor Med Systems $ 1.67 1.2% 541.55 OCC Orthocell Limited $ 1.27 1.2% 307.31 PME Pro Medicus Limited $ 280.98 0.9% 15,316.67 PAR Paradigm Biopharmaceuticals $ 0.31 0.8% 120.72 CTE Cryosite Limited $ 0.75 0.7% 36.61 CHM Chimeric Therapeutic $ 0.00 0.0% 8.06 IXC Invex Therapeutics $ 0.09 0.0% 6.99 COV Cleo Diagnostics $ 0.35 0.0% 27.74 IDT IDT Australia Ltd $ 0.10 0.0% 45.12 EYE Nova EYE Medical Ltd $ 0.13 0.0% 35.52 OCA Oceania Healthc Ltd $ 0.59 0.0% 427.30 EPN Epsilon Healthcare $ 0.02 0.0% 8.29 TD1 Tali Digital Limited $ 0.00 0.0% 3.30 OIL Optiscan Imaging $ 0.13 0.0% 112.77 PER Percheron $ 0.01 0.0% 10.87 OSL Oncosil Medical $ 1.20 0.0% 13.82 BIT Biotron Limited $ 0.00 0.0% 3.32 EOF Ecofibre Limited $ 0.02 0.0% 7.58 TRP Tissue Repair $ 0.19 0.0% 11.19 IBX Imagion Biosys Ltd $ 0.01 0.0% 2.42 SOM SomnoMed Limited $ 0.59 0.0% 129.66 ANR Anatara Ls Ltd $ 0.01 0.0% 1.07 HIQ Hitiq Limited $ 0.02 0.0% 7.57 ADR Adherium Ltd $ 0.01 0.0% 5.31 PSQ Pacific Smiles Grp $ 1.81 -0.3% 291.73 COH Cochlear Limited $ 271.60 -0.4% 17,779.29 CSL CSL Limited $ 247.16 -0.7% 119,986.49 TLX Telix Pharmaceutical $ 25.98 -0.8% 7,546.94 HLS Healius $ 0.88 -0.8% 635.37 ANN Ansell Limited $ 31.19 -0.9% 4,566.62 SNZ Summerset Grp Hldgs $ 10.21 -0.9% 2,461.11 MYX Mayne Pharma Ltd $ 4.80 -1.0% 376.51 RGT Argent Biopharma Ltd $ 0.09 -1.1% 6.86 PNV Polynovo Limited $ 1.27 -1.2% 870.46 PYC PYC Therapeutics $ 1.20 -1.2% 699.91 BDX Bcal Diagnostics $ 0.08 -1.3% 27.45 NEU Neuren Pharmaceuticals $ 13.85 -1.4% 1,765.00 RMD ResMed Inc. $ 37.58 -1.5% 22,360.10 IME Imexhs Limited $ 0.33 -1.5% 17.70 LTP LTR Pharma $ 0.32 -1.5% 34.71 AHC Austco Healthcare $ 0.31 -1.6% 112.86 RHY Rhythm Biosciences $ 0.06 -1.6% 17.87 ONE Oneview Healthcare $ 0.27 -1.9% 202.31 VHL Vitasora Health Ltd $ 0.04 -2.4% 66.24 MSB Mesoblast Limited $ 1.60 -2.4% 1,560.40 CYC Cyclopharm Limited $ 1.18 -2.5% 131.70 AHX Apiam Animal Health $ 0.39 -2.5% 71.74 EBO Ebos Group Ltd $ 34.69 -2.5% 1,365.85 IMM Immutep Ltd $ 0.28 -2.6% 407.57 VIT Vitura Health Ltd $ 0.07 -2.9% 45.03 CUV Clinuvel Pharmaceuticals $ 10.24 -3.0% 457.13 AVH Avita Medical $ 1.89 -3.1% 123.08 NAN Nanosonics Limited $ 4.39 -3.1% 1,282.02 NUZ Neurizon Therapeutic $ 0.15 -3.3% 68.92 MAP Microba Life Sciences $ 0.15 -3.3% 64.94 BMT Beamtree Holdings $ 0.28 -3.4% 81.15 SIG Sigma Health Ltd $ 3.06 -3.5% 17,428.00 MX1 Micro-X Limited $ 0.06 -3.5% 36.70 CGS Cogstate Ltd $ 1.30 -3.5% 219.41 NC6 Nanollose Limited $ 0.05 -3.8% 15.24 RCE Recce Pharmaceutical $ 0.34 -4.2% 90.39 AYA Artrya $ 0.73 -4.6% 82.43 ACW Actinogen Medical $ 0.02 -4.8% 63.54 DXB Dimerix Ltd $ 0.58 -4.9% 326.72 ACL Au Clinical Labs $ 2.78 -5.1% 395.94 EBR EBR Systems $ 1.09 -5.2% 465.57 NXS Next Science Limited $ 0.07 -5.6% 19.57 EMV Emvision Medical $ 1.68 -5.6% 140.67 AT1 Atomo Diagnostics $ 0.02 -5.9% 10.98 PTX Prescient Ltd $ 0.05 -6.0% 37.85 AGN Argenica $ 0.77 -6.1% 98.63 M7T Mach7 Tech Ltd $ 0.35 -6.7% 84.43 BOT Botanix Pharma Ltd $ 0.35 -6.8% 620.71 ZLD Zelira Therapeutics $ 0.46 -7.1% 5.71 SNT Syntara Limited $ 0.07 -7.1% 105.57 CAN Cann Group Ltd $ 0.01 -7.1% 8.09 TYP Tryptamine Ltd $ 0.03 -8.6% 44.45 NTI Neurotech International $ 0.02 -8.7% 22.04 SHG Singular Health $ 0.30 -9.1% 83.31 ECS ECS Botanics Holding $ 0.01 -9.1% 14.26 GSS Genetic Signatures $ 0.49 -9.3% 110.16 CBL Control Bionics $ 0.03 -9.7% 8.84 ILA Island Pharma $ 0.21 -10.6% 49.05 UBI Universal Biosensors $ 0.04 -10.6% 12.52 EMD Emyria Limited $ 0.03 -10.7% 13.75 TRU Truscreen $ 0.02 -11.1% 13.32 RHT Resonance Health $ 0.04 -11.6% 20.22 RAC Race Oncology Ltd $ 1.21 -12.0% 210.22 4DX 4DMedical Limited $ 0.31 -12.9% 146.64 CYP Cynata Therapeutics $ 0.17 -13.2% 37.28 CU6 Clarity Pharma $ 1.91 -13.8% 535.84 CDX Cardiex Limited $ 0.04 -16.1% 17.87 1AI Algorae Pharma $ 0.01 -16.7% 8.44 TRJ Trajan Group Holding $ 0.77 -16.8% 116.57 IMU Imugene Limited $ 0.01 -17.6% 112.01 MEM Memphasys Ltd $ 0.00 -18.2% 7.93 AVE Avecho Biotech Ltd $ 0.00 -20.0% 12.69 BP8 Bph Global Ltd $ 0.00 -20.0% 2.10 VBS Vectus Biosystems $ 0.05 -21.7% 2.50 CTQ Careteq Limited $ 0.01 -23.1% 2.37 1AD Adalta Limited $ 0.00 -33.3% 1.93 Inoviq (ASX:IIQ) rose ~24% in May and got hit with a speeding ticket by the ASX. The oncology play had no particular news out in May and attributed the increase to publication online of an abstract accepted by the American Society of Clinical Oncology (ASCO) for a poster presentation about results of its EXO-OC test for ovarian cancer. Inoviq said the result had already been released in December and referred to in subsequent business updates. "Some shareholders may have missed or misunderstood the significance of our 3 December 2024 ASX release and subsequent related updates noted above and may believe the Abstract contains new or better information, which is materially price sensitive, that is not the case in the company's view. The company said new information to be delivered in the poster presentation at the ASCO annual meeting on June 1 was "considered price sensitive". On June 2 Inoviq announced that new data presented at the ASCO meeting showed its EXO-OC test achieved 77% sensitivity at 99.6% specificity for detecting ovarian cancer at all stages. Clever Culture Systems (ASX:CC5) continued to build momentum in May and was up 26.7% for the month after announcing a positive quarterly update in April, including its second quarter of positive cashflow. Clever Culture is targeting profitability in FY25 and building a substantial sales pipeline to underpin growth in FY26 for its APAS Independence instruments, which remain the only US FDA-cleared AI technology for automated culture plate reading. Lumos Diagnostics (ASX:LDX) rose 7.4% in May after several positive announcements including the largest single purchase order to date for its FebriDx test, a rapid point-of-care (POC) diagnostic designed to differentiate between bacterial and non-bacterial acute respiratory infections. Developer and distributor of cost-saving solutions for hospitals, surgery centres, clinics and healthcare facilities across the US iMedical purchased US$126,000 worth of FebriDx tests. In May Lumos also expanded Medicare reimbursement coverage in the US for FebriDx. By the end of May Lumos had secured reimbursement from six out of seven US Medicare Administrative Contractors (MACs) representing over 85% of US Medicare payment coverage. And Australia's biggest private hospital operator Ramsay Health Care (ASX:RHC) rose 5.1% in May after providing a positive update on its 52.8% stake in European hospitals business Santé, with unaudited group revenue for the nine months period ending March 31, up by 5.1%.
News.com.au
04-05-2025
- Business
- News.com.au
ASX health April winners and losers: Sector rises 2pc in stronger month for markets
The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR and Orthocell, helped boost sentiment in the sector The S&P/ASX 200 Health Care Index was stronger in April, rising 2.16% after being the second-worst performing sector in March. Healthcare followed the broader market upward with the S&P/ASX 200 rallying 3.6% in April as the local bourse held firm against ongoing global geopolitical tensions and economic headwinds. Morgans healthcare analyst Iain Wilkie told Stockhead April was a marked improvement on recent months, partly due to US President Donald Trump softening his stance on tariffs late in April and easing tensions around a potential trade war with China. Wilkie said April marked a solid month of regulatory approvals with EBR Systems (ASX:EBR) gaining US FDA approval for its WISE CRT system – the world's first and only wireless solution for pacing the left side of the heart. Orthocell (ASX:OCC) scored a hattrick of three regulatory approvals in April for its flagship nerve repair product Remplir, including in Canada, Thailand and the US markets. The latest approvals add to pre-existing approvals for Remplir in Australia, New Zealand and Singapore, equating to a significant total addressable market of US$1.8 billion. Regulatory applications for the EU and UK are on track to be submitted in the next six to 12 months. Wilkie said the approvals were also reassuring amid concerns about recent changes at the FDA with reported mass layoffs under Tesla CEO and billionaire Elon Musk's Department of Government Efficiency (DOGE), which were quickly followed by a partial rehiring. "It's good momentum for the sector and shows approvals are still getting through the FDA in time," Wilkie said. "We will see what happens in the next few months." How ASX biotechs performed in April CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP ICR Intelicare Holdings $ 0.01 66.7% 4 NSB Neuroscientific $ 0.05 35.1% 7 AVR Anteris Technologies $ 8.55 31.5% 270 CC5 Clever Culture $ 0.02 28.6% 30 SHG Singular Health $ 0.30 22.9% 77 CHM Chimeric Therapeutic $ 0.01 20.0% 14 IXC Invex Ther $ 0.08 19.1% 6 4DX 4Dmedical Limited $ 0.32 18.5% 135 IMR Imricor Med Sys $ 1.62 17.4% 476 COV Cleo Diagnostics $ 0.41 17.1% 52 DVL Dorsavi Ltd $ 0.01 16.7% 5 DXB Dimerix Ltd $ 0.48 15.7% 425 IDT IDT Australia Ltd $ 0.12 15.0% 49 PME Pro Medicus Limited $ 229.41 14.8% 24,998 AVH Avita Medical $ 3.10 14.0% 369 LDX Lumos Diagnostics $ 0.03 12.5% 21 PGC Paragon Care Limited $ 0.42 12.0% 712 EYE Nova EYE Medical Ltd $ 0.11 10.0% 31 1AI Algorae Pharma $ 0.01 9.1% 10 ECS ECS Botanics Holding $ 0.01 8.3% 16 MVP Medical Developments $ 0.60 8.1% 71 AHX Apiam Animal Health $ 0.41 8.0% 79 ALA Arovella Therapeutic $ 0.09 7.5% 103 OCC Orthocell Limited $ 1.60 6.7% 391 AT1 Atomo Diagnostics $ 0.02 5.9% 13 PNV Polynovo Limited $ 1.21 5.7% 888 IDX Integral Diagnostics $ 2.42 5.7% 871 NAN Nanosonics Limited $ 4.80 5.5% 1,486 CYP Cynata Therapeutics $ 0.20 5.4% 44 VBS Vectus Biosystems $ 0.08 5.3% 4 RHT Resonance Health $ 0.04 5.1% 16 RMD ResMed Inc. $ 36.68 4.9% 54,516 ALC Alcidion Group Ltd $ 0.09 4.9% 117 SIG Sigma Health Ltd $ 3.02 4.9% 35,436 ACL Au Clinical Labs $ 3.12 4.7% 621 COH Cochlear Limited $ 274.59 4.7% 17,937 OCA Oceania Healthc Ltd $ 0.57 4.6% 424 HLS Healius $ 1.46 4.3% 1,106 CU6 Clarity Pharma $ 2.20 4.3% 850 FPH Fisher & Paykel H. $ 31.51 4.2% 19,006 SNZ Summerset Grp Hldgs $ 10.55 4.1% 2,537 TRU Truscreen $ 0.03 3.7% 16 ARX Aroa Biosurgery $ 0.44 3.5% 159 TLX Telix Pharmaceutical $ 27.13 2.3% 9,853 AFP Aft Pharmaceuticals $ 2.34 1.7% 245 CYC Cyclopharm Limited $ 1.17 1.7% 133 SHL Sonic Healthcare $ 26.08 1.2% 12,538 CSL CSL Limited $ 251.13 0.7% 123,518 REG Regis Healthcare Ltd $ 6.81 0.7% 2,208 PCK Painchek Ltd $ 0.04 0.0% 66 SPL Starpharma Holdings $ 0.09 0.0% 38 AVE Avecho Biotech Ltd $ 0.01 0.0% 16 VFX Visionflex Group Ltd $ 0.00 0.0% 10 ACR Acrux Limited $ 0.02 0.0% 9 EPN Epsilon Healthcare $ 0.02 0.0% 8 IVX Invion Ltd $ 0.10 0.0% 8 PAB Patrys Limited $ 0.00 0.0% 5 TD1 Tali Digital Limited $ 0.00 0.0% 3 OSX Osteopore Limited $ 0.02 0.0% 3 IMC Immuron Limited $ 0.07 -0.7% 15 CUV Clinuvel Pharmaceut. $ 11.36 -0.9% 580 BOT Botanix Pharma Ltd $ 0.45 -1.1% 904 EBO Ebos Group Ltd $ 34.20 -1.2% 7,017 NOX Noxopharm Limited $ 0.08 -1.2% 22 M7T Mach7 Tech Limited $ 0.34 -1.5% 84 ONE Oneview Healthcare $ 0.29 -1.7% 216 RAC Race Oncology Ltd $ 1.05 -1.9% 212 CTE Cryosite Limited $ 0.78 -1.9% 38 PTX Prescient Ltd $ 0.05 -2.1% 38 NEU Neuren Pharmaceut. $ 11.66 -2.3% 1,573 SDI SDI Limited $ 0.84 -2.3% 100 RHC Ramsay Health Care $ 33.26 -2.5% 7,860 VHL Vitasora Health Ltd $ 0.04 -2.6% 60 MYX Mayne Pharma Ltd $ 7.03 -2.8% 571 ILA Island Pharma $ 0.16 -3.0% 38 MX1 Micro-X Limited $ 0.06 -3.2% 37 IMM Immutep Ltd $ 0.27 -3.6% 394 OIL Optiscan Imaging $ 0.14 -3.6% 113 PYC PYC Therapeutics $ 1.18 -3.7% 714 IRX Inhalerx Limited $ 0.03 -3.8% 5 CGS Cogstate Ltd $ 1.33 -4.3% 227 VLS Vita Life Sciences.. $ 1.82 -4.5% 99 AGH Althea Group $ 0.02 -4.5% 19 AHC Austco Healthcare $ 0.28 -5.1% 100 TRJ Trajan Group Holding $ 0.81 -5.3% 128 HMD Heramed Limited $ 0.02 -5.3% 15 EMV Emvision Medical $ 1.96 -6.2% 164 NYR Nyrada Inc. $ 0.10 -7.0% 23 TRI Trivarx Ltd $ 0.01 -7.1% 7 IPD Impedimed Limited $ 0.04 -7.3% 71 NUZ Neurizon Therapeutic $ 0.12 -7.7% 69 EZZ EZZ Life Science $ 1.43 -7.7% 65 LGP Little Green Pharma $ 0.12 -8.0% 36 MSB Mesoblast Limited $ 1.80 -8.4% 2,367 BMT Beamtree Holdings $ 0.22 -8.5% 62 PSQ Pacific Smiles Grp $ 1.76 -8.6% 284 IIQ Inoviq Ltd $ 0.37 -8.6% 45 NXS Next Science Limited $ 0.10 -9.1% 26 PER Percheron $ 0.01 -9.1% 10 EMD Emyria Limited $ 0.03 -9.7% 15 ANN Ansell Limited $ 30.30 -10.5% 4,512 ATH Alterity Therap Ltd $ 0.01 -11.1% 78 OSL Oncosil Medical $ 0.00 -11.1% 16 CMP Compumedics Limited $ 0.31 -11.6% 58 AGN Argenica $ 0.68 -11.8% 93 MDR Medadvisor Limited $ 0.10 -12.7% 57 PAR Paradigm Bio. $ 0.29 -13.6% 121 VIT Vitura Health Ltd $ 0.07 -13.8% 48 TYP Tryptamine Ltd $ 0.03 -13.9% 45 BIT Biotron Limited $ 0.00 -14.3% 4 BP8 Bph Global Ltd $ 0.00 -14.3% 1 IME Imexhs Limited $ 0.34 -15.0% 17 NC6 Nanollose Limited $ 0.03 -15.0% 9 ACW Actinogen Medical $ 0.03 -15.6% 83 DOC Doctor Care Anywhere $ 0.08 -15.8% 30 UBI Universal Biosensors $ 0.06 -15.9% 16 AYA Artryalimited $ 0.63 -16.0% 76 EOF Ecofibre Limited $ 0.02 -16.0% 7 TRP Tissue Repair $ 0.22 -17.0% 12 MAP Microbalifesciences $ 0.17 -17.1% 82 CSX Cleanspace Holdings $ 0.39 -17.2% 29 ZLD Zelira Therapeutics $ 0.38 -17.4% 5 LTP Ltr Pharma Limited $ 0.38 -18.5% 73 RCE Recce Pharmaceutical $ 0.29 -18.7% 78 IBX Imagion Biosys Ltd $ 0.01 -18.8% 3 SOM SomnoMed Limited $ 0.45 -18.9% 95 GSS Genetic Signatures $ 0.41 -19.0% 110 CVB Curvebeam Ai Limited $ 0.10 -20.0% 39 CBL Control Bionics $ 0.04 -20.0% 11 CTQ Careteq Limited $ 0.01 -20.0% 3 GLH Global Health Ltd $ 0.09 -21.7% 5 RAD Radiopharm $ 0.02 -22.2% 51 CDX Cardiex Limited $ 0.06 -22.7% 23 UCM Uscom Limited $ 0.02 -23.3% 6 RGT Argent Biopharma Ltd $ 0.13 -23.5% 8 RHY Rhythm Biosciences $ 0.06 -23.8% 19 NTI Neurotech Intl $ 0.03 -24.2% 25 CMB Cambium Bio Limited $ 0.23 -24.6% 4 BDX Bcaldiagnostics $ 0.08 -24.9% 30 IMU Imugene Limited $ 0.02 -25.0% 172 1AD Adalta Limited $ 0.01 -25.0% 4 FRE Firebrickpharma $ 0.07 -25.3% 15 MVF Monash IVF Group Ltd $ 0.84 -26.0% 334 SNT Syntara Limited $ 0.06 -26.3% 99 PIQ Proteomics Int Lab $ 0.36 -28.0% 54 ANR Anatara Ls Ltd $ 0.01 -28.6% 1 ATX Amplia Therapeutics $ 0.05 -30.0% 21 EBR EBR Systems $ 1.22 -30.3% 464 PEB Pacific Edge $ 0.08 -31.8% 61 HIQ Hitiq Limited $ 0.03 -32.4% 11 CAN Cann Group Ltd $ 0.02 -36.0% 10 ADR Adherium Ltd $ 0.01 -36.4% 5 MEM Memphasys Ltd $ 0.01 -44.4% 12 NeuroScientific Biopharmaceuticals (ASX:NSB) rose 35.1% after sealing a deal to acquire StemSmart, a patented stem cell tech from Isopogen WA, giving it full rights to produce next-generation cell therapies using mesenchymal stromal cells (MSCs). Early trial results in Crohn's patients are promising, showing the treatment is safe, effective, and potentially life-changing. To fund the move, NeurosScientific has raised $3.5 million. It also has refreshed its board, including industry veterans and a new chief scientific adviser. Oncology drug developer Chimeric Therapeutics (ASX:CHM) was up 20% in April. The company announced that Emory Winship Cancer Institute in Atlanta was open to enrol patients in the phase 1/2 multi-centre clinical trial (NCT06055439) for CHM CDH17 cell therapy. The phase 1/2 trial is a two-stage study designed to determine a recommended phase II dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs). Imricor Medical Systems (ASX:IMR) also had a strong month, up 17.4% after positive news including launching its pivotal European clinical trial for ventricular tachycardia (VISABL-VT) – marking a series of world-first milestones – and securing CE Mark certification for its Advantage-MR system under the European Union's new Medical Device Regulation (MDR). Imricor is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively. Health-imaging stock ProMedicus (ASX:PME) was up 14.8% in April. The company announced owned US subsidiary Visage Imaging, Inc. had signed a multi-year research collaboration deal with UCSF. "I think ProMedicus just got oversold and it went down to around $150 at one point from just shy of $300," Wilkie said. "These sorts of quality stocks always come back to the fore."
Business Insider
01-05-2025
- Business
- Business Insider
Morgans Keeps Their Buy Rating on Microba Life Sciences Limited (MAP)
In a report released today, Iain Wilkie from Morgans maintained a Buy rating on Microba Life Sciences Limited (MAP – Research Report), with a price target of A$0.32. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wilkie is an analyst with an average return of -11.3% and a 29.69% success rate. Wilkie covers the Healthcare sector, focusing on stocks such as Nanosonics Limited, Pro Medicus Limited, and Mach7 Technologies. Currently, the analyst consensus on Microba Life Sciences Limited is a Moderate Buy with an average price target of A$0.35. The company has a one-year high of A$0.33 and a one-year low of A$0.15. Currently, Microba Life Sciences Limited has an average volume of 180.3K.
News.com.au
27-04-2025
- Business
- News.com.au
ASX medtechs at the forefront of precision, safety and efficiency in healthcare
Certain ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency in healthcare For example, Imricor is pioneering cardiac ablations using MRI instead of traditional x-ray fluoroscopy to treat arrhythmias faster and safer And Singular Health's 3Dicom technology is helping reduce duplicate scans, cutting costs and minimising risks of over-imaging As the medical world strives to diagnose disease earlier for better outcomes, treat conditions more precisely and increase efficiency while reducing healthcare costs, ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency. From early detection of coronary disease, or reducing exposure to radiation for patients and medical staff by replacing x-ray with MRI in cardiac ablation procedures, these medtechs are improving outcomes while delivering greater value through advanced clinical workflows and cost-efficient care. Morgans healthcare analyst Iain Wilkie told Stockhead that the "golden child" of ASX medtechs ProMedicus (ASX:PME) was a prime example of the innovation and AI-driven advancements that make local companies in the sector so attractive. Pro Medicus is a global provider of radiology IT software for hospitals, imaging centres and healthcare networks with its flagship Visage platform delivering ultra-fast imaging and advanced visualisation tools, enabling radiologists to interpret scans remotely – even on mobile devices. "I see Pro Medicus as the best company on the ASX and they have barely put a foot wrong," Wilkie said. "On a valuation basis it's still expensive, but that's been the case for a number of years already and if you're growing 30% year-on-year it doesn't take long to get to a normal valuation. "Key here though is picking it up on weakness, which, coming down from almost $300 to now around $200 is a reasonable entry point and what we have been waiting for a while. 'Like the baby brother' of Pro Medicus Described by Wilkie as "like the baby brother" of Pro Medicus, Mach7 Technologies (ASX:M7T) aims to improve the efficiency and workflow for radiologists, other clinical staff and healthcare organisations with its medical imaging software solutions, Mach7's enterprise imaging solution comprises enterprise data management, enterprise diagnostic viewing and departmental workflow applications. The company's enterprise data management solution consists of a vendor neutral archive (VNA) and data administration tools to enable for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the cloud. Its eUnity enterprise diagnostic viewing technology is an image-viewing solution that makes images accessible on any workstation. Mach7 recently announced the head of formerly ASX-listed Volpara Health Technologies, a leader in medical software for breast cancer screening, had been appointed managing director and CEO. Volpara was acquired by South Korean-based provider of AI-powered solutions for cancer diagnostics and therapeutics Lunit in May 2024 for $292 million. Imricor replaces x-ray with MRI for cardiac ablations Imricor Medical Systems (ASX:IMR) is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively. Cardiac ablations, a procedure that targets and destroys heart cells causing arrhythmias (irregular heartbeats), currently use x-ray fluoroscopy. While effective in visualising hard structures such as ribs, x-ray struggles with soft tissue like the heart, leading to long-term lower success rates, often below 50%, and requiring repeat procedures. Imricor said its MRI-compatible devices for cardiac ablations offer superior ability to visualise the heart and blood vessels, leading to better outcomes, while also reducing exposure of patients and medical staff to radiation. The company is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US Food and Drug Administration (FDA) approval of its products, which it hopes to achieve in 2025. In Europe, where the company has already received regulatory approval for atrial flutter, Imricor recently started its pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT) and has achieved several world-firsts. "Even though it's the same price as existing standard of care, the theory is MRI-guided ablations can improve procedure times so doctors can treat more people per day, with comparable or better patient outcomes (more accurate and durable therapy), and with no radiation," Wilkie said. Singular Health is reducing need for duplicate imaging Singular Health Group Ltd (ASX:SHG) is improving efficiency in health imaging, reducing duplicate scans to save costs but also reduce risks of over-imaging with its 3Dicom technology. A study published this month looked at how many future cancers could result from radiation exposure from annual computed tomography (CT) examinations in the US. The findings suggested that low levels of ionising radiation from CT scans could account for 5% of all new cancer diagnoses in the US. "Every unnecessary CT scan avoided is one less dose of radiation, one less cancer risk, one more patient protected," Singular Health co-founder and CEO Denning Chong said. "Singular Health is building the tools to make that possible – integrating imaging data, empowering clinicians with 3D visualisation, and cutting out waste in a system that desperately needs it." FDA-cleared 3Dicom translates and converts MRIs, CT and PET scans into 3D or virtual reality and extended reality (VR-XR) models. But where Singular Health sees real commercial opportunity is in the viewing, sending, storing and AI analysis of the images for patients and hospitals, managed service organisations and health plans. Singular Health's 3Dicom solution provides the infrastructure to facilitate the use of AI models available in the marketplace on images in transit, to provide stakeholders with more accurate analysis, resulting in reducing misdiagnosis and increasing rates of pre diagnosis. Chong said that in the US in particular, the need to extract better value from images and reduce duplicate imaging costs was critical. The 3Dicom Gateway solution gives each stakeholder standardised viewing, image access, and AI analysis during transit — capabilities they previously lacked. "We are absolutely committed to provide our 3Dicom Gateway solution to not only reduce the unnecessary cost and burden of duplicate imaging, but also to reduce risks to patients such as cancer risks by reducing the need for an unnecessary scan," Chong said. "Even one patient protected is worth the effort." Imagion transforming cancer diagnosis Through its MagSense platform, Imagion Biosystems (ASX:IBX) is aiming to transform cancer diagnosis by introducing molecular imaging to widely available magnetic resonance imaging (MRI). Executive chairman Robert Proulx said MagSense had the potential to improve on current techniques for cancer diagnosis such as x-rays, conventional MRI, CT, ultrasounds and positron emission tomography (PET) by providing a more specific and personalised approach. The MagSense imaging platform involves the use of iron oxide nanoparticles labelled with cancer-specific targeting antibodies, which can then be imaged with MRI. The company is pursuing initial indication in HER2+ breast cancer staging – a form of cancer known to be highly aggressive – with pipeline candidates for prostate and ovarian cancers. "Accuracy or specificity is the big play here and today we have multiple ways of imaging the body and they are all able to find anatomical anomalies," he said. "But they can't tell if these anomalies are a malignant tumour or a benign mass and that is the problem we are trying to solve with our MagSense imaging agent." Proulx said the MagSense particles add specificity so when it shows up on an MRI you know it's there because of the targeting molecules binding to a certain type of tumour. "You have the normal aspect of an MRI with anatomical imaging showing something is unusual in size and shape but also added benefit of the presence of our particle actually showing there are cancer cells because they are bound by the targeting molecule," he said. Imagion recently announced its plans to take the MagSense HER2 breast-cancer imaging agent into a phase II study to be proposed to the FDA in an Investigational New Drug application. Atrya using AI to diagnose coronary artery disease Artrya (ASX:AYA) is using the power of AI for "fast, accurate and non-invasive assessment of coronary artery disease to drive precision medicine, reducing time and costs, and save lives". In March, Artyra received FDA 510(k) clearance for its flagship platform, Salix Coronary Anatomy (SCA), which analyses coronary CT angiography (CCTA) scans and provides the clinician with accurate, real-time information on the existence and extent of high-risk plaque in the arteries – the main cause of death. CEO Mathew Regan said SCA was the first point-of-care approach in 50 years for assessing coronary artery disease, the world's leading cause of death. "For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action," he said in an ASX announcement. "With FDA clearance of Salix Coronary Anatomy, hospitals and clinics can now move beyond traditional diagnostics to a truly proactive approach." With someone in the US suffering a heart attack every 40 seconds, the company forecasts the US market opportunity to be significant, based on 4.4 million CCTA scans annually, and projected to grow at 6.2% per year. Following FDA clearance of the SCA platform Artrya has two further upcoming product submissions including for Salix Coronary Plaque and then Salix Coronary Flow. The company anticipates FDA clearance for both products by the end of 2025, unlocking access to two distinct reimbursement codes for detailed plaque and blood flow analysis in the US healthcare market. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Imricor, Singular Health and Imagion Biosystems are Stockhead advertisers, the companies did not sponsor this article.
Mercury
27-04-2025
- Business
- Mercury
ASX medtechs transforming healthcare
Certain ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency in healthcare For example, Imricor is pioneering cardiac ablations using MRI instead of traditional x-ray fluoroscopy to treat arrhythmias faster and safer And Singular Health's 3Dicom technology is helping reduce duplicate scans, cutting costs and minimising risks of over-imaging As the medical world strives to diagnose disease earlier for better outcomes, treat conditions more precisely and increase efficiency while reducing healthcare costs, ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency. From early detection of coronary disease, or reducing exposure to radiation for patients and medical staff by replacing x-ray with MRI in cardiac ablation procedures, these medtechs are improving outcomes while delivering greater value through advanced clinical workflows and cost-efficient care. Morgans healthcare analyst Iain Wilkie told Stockhead that the "golden child" of ASX medtechs ProMedicus (ASX:PME) was a prime example of the innovation and AI-driven advancements that make local companies in the sector so attractive. Pro Medicus is a global provider of radiology IT software for hospitals, imaging centres and healthcare networks with its flagship Visage platform delivering ultra-fast imaging and advanced visualisation tools, enabling radiologists to interpret scans remotely – even on mobile devices. "I see Pro Medicus as the best company on the ASX and they have barely put a foot wrong," Wilkie said. "On a valuation basis it's still expensive, but that's been the case for a number of years already and if you're growing 30% year-on-year it doesn't take long to get to a normal valuation. "Key here though is picking it up on weakness, which, coming down from almost $300 to now around $200 is a reasonable entry point and what we have been waiting for a while. 'Like the baby brother' of Pro Medicus Described by Wilkie as "like the baby brother" of Pro Medicus, Mach7 Technologies (ASX:M7T) aims to improve the efficiency and workflow for radiologists, other clinical staff and healthcare organisations with its medical imaging software solutions, Mach7's enterprise imaging solution comprises enterprise data management, enterprise diagnostic viewing and departmental workflow applications. The company's enterprise data management solution consists of a vendor neutral archive (VNA) and data administration tools to enable for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the cloud. Its eUnity enterprise diagnostic viewing technology is an image-viewing solution that makes images accessible on any workstation. Mach7 recently announced the head of formerly ASX-listed Volpara Health Technologies, a leader in medical software for breast cancer screening, had been appointed managing director and CEO. Volpara was acquired by South Korean-based provider of AI-powered solutions for cancer diagnostics and therapeutics Lunit in May 2024 for $292 million. Imricor replaces x-ray with MRI for cardiac ablations Imricor Medical Systems (ASX:IMR) is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively. Cardiac ablations, a procedure that targets and destroys heart cells causing arrhythmias (irregular heartbeats), currently use x-ray fluoroscopy. While effective in visualising hard structures such as ribs, x-ray struggles with soft tissue like the heart, leading to long-term lower success rates, often below 50%, and requiring repeat procedures. Imricor said its MRI-compatible devices for cardiac ablations offer superior ability to visualise the heart and blood vessels, leading to better outcomes, while also reducing exposure of patients and medical staff to radiation. The company is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US Food and Drug Administration (FDA) approval of its products, which it hopes to achieve in 2025. In Europe, where the company has already received regulatory approval for atrial flutter, Imricor recently started its pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT) and has achieved several world-firsts. "Even though it's the same price as existing standard of care, the theory is MRI-guided ablations can improve procedure times so doctors can treat more people per day, with comparable or better patient outcomes (more accurate and durable therapy), and with no radiation," Wilkie said. Singular Health is reducing need for duplicate imaging Singular Health Group Ltd (ASX:SHG) is improving efficiency in health imaging, reducing duplicate scans to save costs but also reduce risks of over-imaging with its 3Dicom technology. A study published this month looked at how many future cancers could result from radiation exposure from annual computed tomography (CT) examinations in the US. The findings suggested that low levels of ionising radiation from CT scans could account for 5% of all new cancer diagnoses in the US. "Every unnecessary CT scan avoided is one less dose of radiation, one less cancer risk, one more patient protected," Singular Health co-founder and CEO Denning Chong said. "Singular Health is building the tools to make that possible – integrating imaging data, empowering clinicians with 3D visualisation, and cutting out waste in a system that desperately needs it." FDA-cleared 3Dicom translates and converts MRIs, CT and PET scans into 3D or virtual reality and extended reality (VR-XR) models. But where Singular Health sees real commercial opportunity is in the viewing, sending, storing and AI analysis of the images for patients and hospitals, managed service organisations and health plans. Singular Health's 3Dicom solution provides the infrastructure to facilitate the use of AI models available in the marketplace on images in transit, to provide stakeholders with more accurate analysis, resulting in reducing misdiagnosis and increasing rates of pre diagnosis. Chong said that in the US in particular, the need to extract better value from images and reduce duplicate imaging costs was critical. The 3Dicom Gateway solution gives each stakeholder standardised viewing, image access, and AI analysis during transit — capabilities they previously lacked. "We are absolutely committed to provide our 3Dicom Gateway solution to not only reduce the unnecessary cost and burden of duplicate imaging, but also to reduce risks to patients such as cancer risks by reducing the need for an unnecessary scan," Chong said. "Even one patient protected is worth the effort." Imagion transforming cancer diagnosis Through its MagSense platform, Imagion Biosystems (ASX:IBX) is aiming to transform cancer diagnosis by introducing molecular imaging to widely available magnetic resonance imaging (MRI). Executive chairman Robert Proulx said MagSense had the potential to improve on current techniques for cancer diagnosis such as x-rays, conventional MRI, CT, ultrasounds and positron emission tomography (PET) by providing a more specific and personalised approach. The MagSense imaging platform involves the use of iron oxide nanoparticles labelled with cancer-specific targeting antibodies, which can then be imaged with MRI. The company is pursuing initial indication in HER2+ breast cancer staging – a form of cancer known to be highly aggressive – with pipeline candidates for prostate and ovarian cancers. "Accuracy or specificity is the big play here and today we have multiple ways of imaging the body and they are all able to find anatomical anomalies," he said. "But they can't tell if these anomalies are a malignant tumour or a benign mass and that is the problem we are trying to solve with our MagSense imaging agent." Proulx said the MagSense particles add specificity so when it shows up on an MRI you know it's there because of the targeting molecules binding to a certain type of tumour. "You have the normal aspect of an MRI with anatomical imaging showing something is unusual in size and shape but also added benefit of the presence of our particle actually showing there are cancer cells because they are bound by the targeting molecule," he said. Imagion recently announced its plans to take the MagSense HER2 breast-cancer imaging agent into a phase II study to be proposed to the FDA in an Investigational New Drug application. Listen to Health Kick Podcast: Imagion's cancer imaging alternative Atrya using AI to diagnose coronary artery disease Artrya (ASX:AYA) is using the power of AI for "fast, accurate and non-invasive assessment of coronary artery disease to drive precision medicine, reducing time and costs, and save lives". In March, Artyra received FDA 510(k) clearance for its flagship platform, Salix Coronary Anatomy (SCA), which analyses coronary CT angiography (CCTA) scans and provides the clinician with accurate, real-time information on the existence and extent of high-risk plaque in the arteries – the main cause of death. CEO Mathew Regan said SCA was the first point-of-care approach in 50 years for assessing coronary artery disease, the world's leading cause of death. "For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action," he said in an ASX announcement. "With FDA clearance of Salix Coronary Anatomy, hospitals and clinics can now move beyond traditional diagnostics to a truly proactive approach." With someone in the US suffering a heart attack every 40 seconds, the company forecasts the US market opportunity to be significant, based on 4.4 million CCTA scans annually, and projected to grow at 6.2% per year. Following FDA clearance of the SCA platform Artrya has two further upcoming product submissions including for Salix Coronary Plaque and then Salix Coronary Flow. The company anticipates FDA clearance for both products by the end of 2025, unlocking access to two distinct reimbursement codes for detailed plaque and blood flow analysis in the US healthcare market. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Imricor, Singular Health and Imagion Biosystems are Stockhead advertisers, the companies did not sponsor this article. Disclosure: The journalist held shares in Mach7 Technologies at the time of writing this article. Originally published as ASX medtechs at the forefront of precision, safety and efficiency in healthcare
